Dr. Prasanth Manohar, Ph.D., – Page 18 – PHAGElogist

Bacteriophage endolysin powders for therapy

A new article punished in the International Journal of Pharmaceutics describes the "Bacteriophage endolysin powders for inhaled delivery against pulmonary infections" by Wang et al. https://doi.org/10.1016/j.ijpharm.2023.122679 Abstract Endolysins are bacteriophage-encoded…

Targeting Phage Therapy 2023

The 6th World Congress on Targeting Phage Therapy 2023 will take place on June 1-2 at IRIS, Paris, France. Targeting Phage 2023: Questions, Controversies, and What is Next? Targeting Phage…

Regulatory pathway needs to be developed to make the most of phages

A regulatory pathway needs to be developed if the UK is to reap the benefits of bacteriophage therapy, Applied Microbiology International (AMI) has warned. France, Belgium and Poland are already…

Publish in this special issue to communicate your phage research

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Microbiology". Deadline for manuscript submissions: 12 May 2023 Special Issue "Bacteriophages: Infection, Genetics and Therapy" https://www.mdpi.com/journal/life/special_issues/196IPXRO2G Dear Colleagues, Bacteriophages…

The dynamic interplay of bacteriophage, bacteria and the mammalian host

Title: "The dynamic interplay of bacteriophage, bacteria and the mammalian host during phage therapy" AbstractFor decades, biomedically-centered studies of bacteria have focused on mechanistic drivers of disease in their mammalian…

Personalized Inhaled Bacteriophage Therapy Decreases MDR P. aeruginosa

In this fantastic work, Chan and colleagues show that using phage to treat P. aeruginosa lung infections in people with cystic fibrosis can lower P. aeruginosa levels, improve lung function, and drive…

PhageDiag project received grants from the EIC Accelerator Fund

Vésale Bioscience, a research and development company of solutions and treatments using phage therapy for multi-resistant infections, has announced it has received €1.8m (£1.6m) in grants from the European Innovation Council…

First-in-human application of double-stranded RNA bacteriophage

Publication: Brief Report - "First-in-human application of double-stranded RNA bacteriophage in the treatment of pulmonary Pseudomonas aeruginosa infection" by Li et al. https://doi.org/10.1111/1751-7915.14217 Abstract A double-stranded RNA (dsRNA) phage phiYY is able…

Adaptive Phage Therapeutics Announces First Patient Dosed in the PHAGE Clinical Trial

Adaptive Phage Therapeutics, Inc., (APT) a clinical-stage biotechnology company advancing the APT phage bank, the world’s largest therapeutic phage initiative for treatment of bacterial infectious diseases, today announced the first…

Are bacteriophages the new antibiotics?

Bacteriophages, viruses that infect bacteria, may be used as an alternative treatment option when antibiotics fail. Leiden researchers have studied the structure and function of a novel bacteriophage that could…